REGN7508 for Preventing Blood Clots After Knee Replacement
This study is looking at an experimental drug, REGN7508, to see how well it prevents blood clots (Venous Thromboembolism or VTE) after total knee replacement surgery. Researchers are comparing REGN7508 to two other common medications, Apixaban and Enoxaparin, and also to a placebo (an inactive substance). The study aims to understand if REGN7508 is effective in preventing these clots and to learn about any side effects it might cause. You might be able to join if you are an adult, 18 years or older, having your first total knee replacement on one side, are in good health, and weigh 130 kg (about 286 lbs) or less. The main goal is to see how many people develop blood clots by about 14 days after surgery. The current status of this study is unclear.
- Study design
- This interventional study plans to enroll 2000 participants. It compares REGN7508, Apixaban, Enoxaparin, and a placebo.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed through a day 12 visit, which is approximately 14 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
At a glance
Conditions
Where it's being run
46 sites across 25 statesStudy leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of the composite endpoint of asymptomatic or symptomatic Venous Thromboembolism (VTE) [including VTE-related death]Through day 12 visit, approximately 14 days